Production of plasminogen activator inhibitor type-2 in human peripheral blood monocytes upregulated in vitro by the quinoline-3-carboxamide, Linomide

Fibrinolysis

Volumn 10, Issue 5-6, 1996, Pages 277-283

  Billstrom A ^a   Kinnby, B ^c   Lecander, L ^b   Astedt, B ^a,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 2; ROQUINIMEX;

ARTICLE; BLOOD; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030447587     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80008-7     Document Type: Article

References (47)

1. Hart D A, Rehemtulla A. Plasminogen activators and their inhibitors: Regulators of extracellular proteolysis and cell function. Comp Biochem Physiol 1988; 90B: 691-708.
2. Vassalli J-D, Sappino A-P, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991: 88: 1067-1072.
3. Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 1976; 261: 595-597.
4. Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992; 6: 3-26.
5. Andreasen P A, Georg B, Lund L R, Riccio A, Stacey S N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19.
6. Kruithof E K O, Baker M S, Bunn C L. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-4024.
7. Dear A E, Medcalf R L. The cellular and molecular biology of plasmlnogen activator inhibitor type-2. Fibrinolysis 1995; 9: 321-330.
8. Hamilton J A, Whitty G A, Wojta J, Gallichio M, McGrath K, lanches G. Regulation of plasminogen activator inhibitor-1 levels in human monocytes. Cell Immun 1993; 152: 7-17.
9. Baker M S, Green S P, GOSS N, Katrantzis M, Doe W F. Plasminogen activator inhibitor 2 (PAI-2) is not inactivated by exposure to oxidants which can be released from activated neutrophils. Biochem Biophys Res Commun 1990; 166: 993-1000.
10. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in human cancer. Int J Cancer 1992; 50: 345-348.
11. Bouchet C, Spyratos F, Martin P M, Hacene K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994; 69: 398-405.
12. Foekens J A, Buessecker F, Peters H A, Krainick U, van Putten W L J, Look M P, Klijn J G M, Kramer M D. Plasminogen activator inhibitor-2: Prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55: 1423-1427.
13. Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: Immunohistochemical study. Am J Gastroenterol 1993; 88: 1928-1933.
14. Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Plasminogen activators and their inhibitors in non-small cell lung cancer. Cancer 1994; 73: 1398-1405.
15. Nakamura M, Konno T, Tanaka Y, Maruo Y, Nishino N, Aoki K, Baba S, Sakaguchi S, Takada Y, Takada A. Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissue. Thromb Res 1992; 65: 709-719.
16. Baker M S, Bleakley P, Woodrow G C, Doe F. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 1990; 50: 4676-4684.
17. Kirchheimer J C, Remold H G. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J Immun 1989; 143:2634-2639.
18. Laug W E, Cao X R, Yu Y B, Shimada H, Kruithof E K O. Inhibition of invasion of HT 1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 1993; 53: 6051-0057.
19. Mueller B M, Yu Y B, Laug W E. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in SCID/SCID mice. Proc Natl Acad Sci USA 1995; 92: 205-209.
20. Shinkfield M N F, Burnand K G, Ballance D J, Zitka M, Eastham D. The effect of recombinant plasminogen activator inhibitor-2 (PAI2) on the growth of a human tumor cell line in-vitro and in-vivo. Fibrinolysis 1992; 6: 59-63.
21. Astedt B, Billström A, Lecander I. Urokinase-producing tumour growth in SCID mice inhibited by recombinant PAI-2. Fibrinolysis 1995; 9: 175-177.
22. Karussis D M, Lehmann D, Slavin S, Vourka-Karussis U, MizrachiKoll R, Ovadia H, Kalland T, Ambramsky O. Treatment of chronicrelapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Unomide (quinoIine-3carboxamide). Proc NaÜ Acad Sci USA 1993; 90: 6400-6404.
23. Slavin S, Sidi H, Weiss L, Rosenman E, Kalland T, Gross D. linomide, a new treatment for autoimmune diseases: The potential in type 1 diabetes. Diabetes Metab Rev 1993; 9: 311-315.
24. Ichikawa T, Lamb J C, Christensson P I, Hartley-Asp B, Isaacs J T. The antitumor effects of the Quinoline-3-Carboxamide Linomide on Dunning R-3327 rat prostatic cancers. Cancer Res 1992; 52: 3022-3028.
25. Borgström P, Torres Filho IP, Hartley-Asp B. Inhibition of angiogenesis and métastases of the Lewis lung cell carcinoma by the quinoline-3-carboxamide, Linomide. Anticancer Res 1995; 15: 719-728.
26. Sabzevari H, Koo G C, Szalay J. The effect of linomlde on growth and metastasis of mammary adenocarcinoma in the Fischer 344 rat. JExp Clin Cancer Res 1994; 13:21-30.
27. Kalland T. Effects of immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 1986; 46:3018-3022.
28. Vukanovic, J, Passaniti A, Hirata T, Traystman R J, Hartley-Asp B, Isaacs JT. Antiangiogenic effects of the quinoline-3-carboxamide Linomide. Cancer Res 1993; 53: 1833-1837.
29. Borgström P, Torres Filho IP, Vajkoczy P, Strandgarden K, Polacek J, Hartley-Asp B. The quinoline-3-carboxamide Linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol 1994; 34: 280-286.
30. Kinnby B, Ästedt B, Casslen B. Reduction of PAI-2 production in cultured human peripheral blood monocytes by estradiol and progesterone - No effect on t-PA, u-PA and PAI-1. Fibrinolysis 1995; 9: 152-156.
31. Lecander I, Ästedt B. Specific plasminogen activator inhibitor of placental type, PAI-2, occurring in amniotic fluid and cord blood. J Lab Clin Med 1987; 110: 602-605.
32. Nilsson IM, Olow B. Fibrinolysis induced by streptokinase in man. Acta Chir Scand 1962; 123: 247-266.
33. Haverkate F, Traas D W. Dose-response curves in the fibrin plate assay. Fibrinolytic activity of proteases. Thrombos Diathes Haemorrh 1974; 32: 356-365.
34. Ny T, Hansson L, Lawrence D, Leonardsson G, Ästedt B. Plasminogen activator inhibitor type 2 cDNA transfected into Chinese hamster ovary cells is stably expressed but not secreted. Fibrinolysis 1989; 3: 189-196.
35. Young W S. In situ hybridization histochemistry. Handbook of Chemical Neuroanatomy 1990; 8: 481-512.
36. Cox K H, DeLeon D V, Angerer L M, Angerer R C. Detection of mRNA in sea urchin embryos by in situ hybridization using asymmetric RNA probes. Dev Biol 1984; 101:485-502.
37. 7. Whitfleld J H J, Brady L S, Smith M A, Mamalaki E, Fox R J, Herkenham M. Optimization of cRNA probe in situ hybridization methodology for localization of glucocorticoid receptor mRNA in rat brain: A detailed protocol. Cell Mol Neurobiol 1990; 10: 145-157.
38. Simmons D M, Arriza J L, Swanson L W. A complete protocol for in situ hybridization of messenger RNA in brain and other tissues with radiolabeled single-stranded RNA probes. J Histotechnol 1989; 12: 169-181.
39. Montgomery D C. In: Design and analysis of experiments, second edition. New York: John Wiley& Sons, 1984: 189-240.
40. Schwartz B S, Monroe M C, Bradshaw J D. Endotoxin-induced production of plasminogen activator inhibitor by human monocytes is autonomous and can be inhibited by lipid X. Blood 1989; 73:2188-2195.
41. Sprengers E D, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387.
42. Myoung H L, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81: 2357-2362.
43. de Bono D. Significance of raised plasma concentrations of tissuetype plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 1994; 71 : 504-507.
44. Erickson L A, Fici G J, LundJ E, Boyle T P, Polites H G, Marotti K R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-76.
45. Andren-Sandberg A, Lecander I, Martinsson G, Ästedt B. Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma. Cancer 1992; 69: 2884-2887.
46. Lang I M, Marsh J J, Olman M A, Moser K M, Loskutoff D J, Schleef R R. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994; 89: 2715-2721.
47. Manchanda N, Schwartz B S. Lipopolysaccharide-induced modulation of human monocyte urokinase production and activity. J Immun 1990; 145: 4174-4180.